Dipeptidyl peptidase‐4 inhibitors (DPP‐4is) were selected as the comparator group, as both SGLT2 inhibitors and DPP‐4 inhibitors are newer classes of oral antidiabetic agents and are typically prescribed to patients at similar stages of T2DM management [22]. Here, SLC5A2 is linked to type 2 diabetes mellitus.